Entering text into the input field will update the search result below

ARCA Biopharma: Activist's Pressure Could Make This Into A Liquidation Play

May 03, 2022 11:50 AM ETARCA biopharma, Inc. (ABIO)5 Comments


  • Activist is pushing ARCA biopharma to stop new developments and return cash to shareholders.
  • Subsequently, management has started a strategic review.
  • The company's cash position (minus liabilities) stands at $3.19/share offering a potential 45% upside if things play out according to the activist's demands.

Researcher working in a biochemist laboratory

Luis Alvarez/DigitalVision via Getty Images

ARCA biopharma, Inc. (NASDAQ:ABIO) is a clinical-stage biopharma company that has been destroying shareholder value for decades and has recently failed its COVID treatment program. Around that time, an activist Cable Car Capital started aggressively buying

ABIO balance sheet

Q1'22 financial report

This article was written by

Dalius Taurus profile picture
High conviction event-driven investments. Actionable and catalyst rich.

Focused on event-driven trades and special situations. Always looking for an edge.  

The last 10 years of my life have been devoted to the investment world, with event-driven opportunities being my bread and butter. I was and still am surprised by the extent the markets are mis-pricing the risks/rewards in some situations - markets are very far from being efficient and your own research can give you a very sizable edge.

I have considerable professional experience in investment banking and strategy consulting, as well as a number of finance degrees under my belt. My entrepreneurial spirit has also enabled me to launch a number of new businesses, some of which have succeeded and some of which have failed. I am lucky enough to have skills in both business development and investment analysis - this is a winning combination that allows me to quickly recognize and filter out the most attractive investment opportunities in the market.

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in ABIO over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.